Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study
- 作者: Korotaeva T1, Loginova E1, Getiya T1, Nasonov E1,2
-
隶属关系:
- V.A. Nasonova Scientific and Research Institute of Rheumatology, Department of Psoriatic arthritis
- I.M. Sechenov First Moscow State Medical University, Department of Rheumatology
- 期: 卷 90, 编号 5 (2018)
- 页面: 22-29
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32732
- DOI: https://doi.org/10.26442/terarkh201890522-29
- ID: 32732
如何引用文章
全文:
详细
作者简介
T Korotaeva
V.A. Nasonova Scientific and Research Institute of Rheumatology, Department of Psoriatic arthritis
Email: tatianakorotaeva@gmail.com
д.м.н., в.н.с., зав. лаб. диагностики и инновационных методов лечения псориатического артрита Moscow, Russia
E Loginova
V.A. Nasonova Scientific and Research Institute of Rheumatology, Department of Psoriatic arthritisк.м.н., с.н.с. лаб. диагностики и инновационных методов лечения псориатического артрита Moscow, Russia
T Getiya
V.A. Nasonova Scientific and Research Institute of Rheumatology, Department of Psoriatic arthritisврач-исследователь лаб. диагностики и инновационных методов лечения псориатического артрита Moscow, Russia
E Nasonov
V.A. Nasonova Scientific and Research Institute of Rheumatology, Department of Psoriatic arthritis; I.M. Sechenov First Moscow State Medical University, Department of Rheumatologyд.м.н., акад. РАН, научный руководитель ФГБНУ «НИИ ревматологии им. В.А. Насоновой» Moscow, Russia
参考
- Helliwell P.S, Ruderman E. Natural history, prognosis, and Socioeconomic aspects of psoriatic arthritis. Rheum Dis Clin N Am. 2015; 4: 581-591. doi: 10.1016/j.rdc.2015.07.004
- Egeberg A, Kristensen L.E, Thyssen J.P, Gislason G.H, Gottlieb A.B, Coates L.C, Jullien D, Gisondi P, Gladman D.D, Skov L, Mallbris L. Incedence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. Ann Rheum Dis. 2017;0:1-7. doi: 10.1136/annrheumdis-2016-210579
- Kristensen L.E, Jorgensen T.D, Christensen R., Gudbergsen H, Dreyer L, Ballegaard C, Jacobsson L.T.H, Strand V, Mease PJ, Kjellberg J. Societal costs and patients‘ experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. Ann Rheum Dis. 2017;0:1-7. doi: 10.1136/annrheumdis-2016-210579
- Coates L.C, Mease P, Kirhman B, Mc Leod L.D, Mpofu S, Karyekar C, Gandhi K. Secukinumab improves minimal disease activity response rates in patients with active psoriatic arthritis: data from the randomized phase 3 study, Future 2. Ann Rheum Dis. 2016;75(Suppl 2): 605. doi: 10.1136/annrheumdis-2016-EULAR.3949
- Theander E, Husmark T, Alenius G.M, Larsson P.T, Teleman A, Geijer M, Lindqvist U.R. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow - up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2013; 73(2): 407-13
- Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, Gladman D, Leszczyński P, Vitek P, Turkiewicz A, Khraishi M, Fitz Gerald O, Landewé R, de Longueville M, Hoepken B, Peterson L, van der Heijde D. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior anti tumor necrosis factor exposure. RMD Open. 2015 Jun 25;1(1): e000119. doi: 10.1136/rmdopen-2015-000119
- Lubrano E, Parsons W.J, Perrotta F.M. Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors. J Rheumatol. 2016;43:918-23. doi: 10.3899/jrheum.151404
- Kavanaugh A. Psoriatic arthritis: treat - to - target. Clin Exp Rheumatol. 2012; 30 (Suppl 73):123-125.
- Gossec L, Smolen J.S, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete J.D, Damjanov N, Fitz Gerald O, Haglund E, Helliwell P, Kvien T.K, Lories R, Luger T, Maccarone M, Marzo-Ortega H, Mc Gonagle D, McInnes I.B, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016; 75:499-5. doi: 10.1136/annrheumdis-2015-208337
- Smolen J.S, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman D.D, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch F.V.D, Coates L.C, Emery P, Gensler L.S, Gossec L, Helliwell P, Jongkees M, Kvien T.K, Inman R.D, McInnes I.B, Maccarone M, Machado P.M, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, Heijde D.V. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2017; 0:1-15. doi: 10.1136/Ann Rheum Dis-2017-211734
- Coates L.C, Moverley A.R, Mc Parland L, Brown S, Navarro-Coy N, O'Dwyer J.L, Meads D.M, Emery P, Conaghan P.G, Helliwell P.S. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open - label, randomised controlled trial. Lancet. 2015 Dec 19;386(10012):2489-98. doi: 10.1016/S0140-6736(15)00347-5
- Coates L.C, Helliwell P.S. Treating to target in psoriatic arthritis: How to implement in clinical practice. Ann Rheum Dis. 2015;4:640-643. doi: 10.1097/bor.0000000000000140
- Коротаева Т.В., Логинова Е.Ю., Каратеев Д.Е., Глазков А.А., Насонов Е.Л. Стратегия «Лечение до достижения цели» при раннем псориатическом артрите (предварительные результаты исследования РЕМАРКА). Науч - практич ревматол. 2016;54 (Прил. 2): 71-75. doi.org/10.14412/1995-4484-2014-376-380
- Coates L.C, Helliwell P.S. Disease measurement - enthesitis, skin, nails, spine and dactylitis. Best Pract Res Clin Rheumatol. 2010; 24(5):659-70. doi: 10.1016/j.berh.2010.05.004
- Coates L.C, Helliwell P.S. Methotrexate efficacy in the Tight Control in Psoriatic Arthritis (TICOPA) study. J Rheumatol. 2016; 43(2):356-361. doi: 10.3899/jrheum.150614
- Bianchi G, Caporali R, Mattana P. Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. Adv Ther. 2016; 33:369-378. doi: 10/1007/s12325-016-0295-8
- Hazlewood G.S, Thorne J.C, Pope J.E, Lin D, Tin D, Boire G, Haraoui B, Hitchon C.A, Keystone E.C, Jamal S, Bykerk V.P. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis. 2016; 75: 1003-1008. doi: 10.1136/annrheumdis-2014-206504
- Sheane B.J, Thavaneswaran A, Gladman D.D, Chandran V. Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis. J Rheumatol. 2016; 43 (9): 1718-1723. doi: 10.3899/jrheum.160111